中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

222 records (took 0.026 seconds)

    DELICIOUS MEDICINAL COMPOSITION FOR COMPANION ANIMAL
    4.
    发明专利
    DELICIOUS MEDICINAL COMPOSITION FOR COMPANION ANIMAL 审中-公开

    公开(公告)号：JP2002255858A

    公开(公告)日：2002-09-11

    申请号：JP2002047380

    申请日：2002-02-25

    Applicant: PFIZER PROD INC

    Inventor： KASRAIAN KASRA ,  THOMBRE AVINASH GOVIND

    IPC: A61K47/46 ,  A23K1/16 ,  A23K1/18 ,  A61K9/00 ,  A61K9/20

    Abstract: PROBLEM TO BE SOLVED: To provide a medicinal composition enabling excellent treating compliance and convenience and larger satisfaction of pet owner. SOLUTION: In this delicious medicinal composition for orally administering to companion animals, comprising a pharmaceutically active substance combined with a palatability-improving agent and a pharmaceutically permissible carrier in a pharmaceutically effective amount, the palatability-improving agent is derived from non-meat and non-fish and the medicinal composition exists in enough amount to make the medicinal composition delicious for companion animal, with the proviso that when the palatability-improving agent is yeast, the agent exists in an amount of about 2 to about 25 wt.% based on the delicious medicinal composition.

    Method, dosage form and kit for administering ziprasidone without food
    6.
    发明专利
    Method, dosage form and kit for administering ziprasidone without food 审中-公开
    方法，用于管理不含食物的ZIPRASIDONE的剂型和试剂盒

    公开(公告)号：JP2009215293A

    公开(公告)日：2009-09-24

    申请号：JP2009052853

    申请日：2009-03-06

    Applicant: Pfizer Inc ,  ファイザー・インク

    Inventor： CURATOLO WILLIAM JOHN ,  HERBIG SCOTT MAX ,  THOMBRE AVINASH GOVIND ,  SHAH JAYMIN CHANDRAKANT ,  SHAMBLIN SHERI LYNN ,  LUKAS TIMOTHY ,  BRETT WILLIAM CALDWELL ,  FRIESEN DWAYNE THOMAS ,  LYON DAVID KEITH ,  CRAIG CHRISTOPHER DONOVAN

    IPC: A61K31/496 ,  A61K9/48 ,  A61K47/38 ,  A61K47/40 ,  A61P25/00

    CPC classification number: A61K31/496

    Abstract: PROBLEM TO BE SOLVED: To provide methods, dosage forms and kits for administering ziprasidone without food.
    SOLUTION: The present invention provides methods, dosage forms and kits for treating a CNS (central nervous system) disorder in a human with an effective amount of ziprasidone when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, comprising administering a solid oral dosage form comprising an amount of ziprasidone effective to treat the CNS disorder to the human in a fasted state, wherein the area under the serum concentration versus time curve (AUC
    0-inf ) of the ziprasidone in the human subsequent to the administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC
    0-inf ) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.
    COPYRIGHT: (C)2009,JPO&INPIT

    Abstract translation: 要解决的问题：提供无食物管理齐拉西酮的方法，剂型和试剂盒。 解决方案：本发明提供了当人处于禁食状态时用有效量的齐拉西酮治疗人的CNS（中枢神经系统）病症的方法，剂型和试剂盒。 在一个实施方案中，本发明涉及一种用于治疗人类中枢神经系统疾病的方法，其包括施用固体口服剂型，所述口服剂型包含一定量的齐拉西酮，其有效地在禁食状态下治疗所述人类的CNS病症， 在给药后人中齐拉西酮的血清浓度对时间曲线（AUC 0-inf ）为齐拉西酮血清浓度对时间曲线下平均面积的70％至140％（AUC < SB> 0-inf ），其是将含有相同量的齐拉西酮的对照齐拉西酮立即释放口服胶囊给予给予状态的人群。 版权所有（C）2009，JPO＆INPIT

    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS
    10.
    发明申请
    AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS 审中-公开
    AZITHROMYCIN剂型减少副作用

    公开(公告)号：WO2005053650A8

    公开(公告)日：2005-12-01

    申请号：PCT/IB2004001654

    申请日：2004-05-14

    Applicant: PFIZER PROD INC ,  HAGEN TIMOTHY ARTHUR ,  HERBIG SCOTT MAX ,  LO JULIAN BELKNAP ,  THOMBRE AVINASH GOVIND ,  APPEL LEAH ELIZABETH ,  CREW MARSHALL DAVID ,  FRIESEN DWAYNE THOMAS ,  LYON DAVID KEITH ,  MCCRAY SCOTT BALDWIN ,  WEST JAMES BLAIR

    Inventor： HAGEN TIMOTHY ARTHUR ,  HERBIG SCOTT MAX ,  LO JULIAN BELKNAP ,  THOMBRE AVINASH GOVIND ,  APPEL LEAH ELIZABETH ,  CREW MARSHALL DAVID ,  FRIESEN DWAYNE THOMAS ,  LYON DAVID KEITH ,  MCCRAY SCOTT BALDWIN ,  WEST JAMES BLAIR

    IPC: C07H17/00 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/7052 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/44 ,  A61P31/04

    CPC classification number: A61K9/1611 ,  A61K9/143 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K31/7052

    Abstract: An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

    Abstract translation: 包含阿奇霉素和有效量的碱化剂的口服剂型。 优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包含阿奇霉素，单山嵛酸甘油酯，二苯乙酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。另外公开的是包含阿奇霉素，有效量的碱化剂和 一辆车。 优选地，阿奇霉素是多颗粒形式，其中所述多颗粒包括阿奇霉素，甘油单山嵛酸甘油酯，二苯甲酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 还公开了一种减少与向哺乳动物施用阿奇霉素相关的胃肠道副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠道副作用的频率低于施用相等剂量 的阿奇霉素。没有所述碱化剂的阿奇霉素的进一步公开是一种在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量 的碱性试剂。另外公开了包含阿奇霉素，表面活性剂的阿奇霉素多颗粒; 和药学上可接受的载体。

Patent Agency Ranking